Extrawell Pharmaceutical Holdings Limited (0858.HK)
HKD 0.05
(2.04%)
HKD 0.05
(2.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.16 Million HKD | 26.82% |
| 2022 | -11.15 Million HKD | 39.57% |
| 2021 | -18.45 Million HKD | -164.25% |
| 2020 | -6.98 Million HKD | 57.23% |
| 2019 | -16.33 Million HKD | 3.77% |
| 2018 | -16.97 Million HKD | 1.42% |
| 2017 | -17.21 Million HKD | -14.72% |
| 2016 | -15 Million HKD | -3188.07% |
| 2015 | 486 Thousand HKD | 101.01% |
| 2014 | -48.2 Million HKD | -227.57% |
| 2013 | 37.78 Million HKD | 215.64% |
| 2012 | 11.97 Million HKD | 41.2% |
| 2011 | 8.47 Million HKD | 66.16% |
| 2010 | 5.1 Million HKD | -60.1% |
| 2009 | 12.78 Million HKD | 60.03% |
| 2008 | 7.99 Million HKD | 212.51% |
| 2007 | 2.55 Million HKD | -73.08% |
| 2006 | 9.5 Million HKD | 24.92% |
| 2005 | 7.6 Million HKD | 108.88% |
| 2004 | -85.63 Million HKD | -169.85% |
| 2003 | -31.73 Million HKD | -155.33% |
| 2002 | 57.35 Million HKD | 11.17% |
| 2001 | 51.59 Million HKD | 89.62% |
| 2000 | 27.2 Million HKD | 53.66% |
| 1999 | 17.7 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -8.16 Million HKD | 26.82% |
| 2023 Q2 | -3.32 Million HKD | 0.0% |
| 2023 Q4 | -3.46 Million HKD | 0.0% |
| 2022 Q4 | -3.12 Million HKD | 0.0% |
| 2022 FY | -11.15 Million HKD | 39.57% |
| 2022 Q2 | -8.03 Million HKD | 0.0% |
| 2021 FY | -18.45 Million HKD | -164.25% |
| 2021 Q2 | -3.46 Million HKD | 0.0% |
| 2021 Q4 | -14.99 Million HKD | 0.0% |
| 2020 Q4 | -3.37 Million HKD | 0.0% |
| 2020 FY | -6.98 Million HKD | 57.23% |
| 2020 Q2 | -3.64 Million HKD | 0.0% |
| 2019 FY | -16.33 Million HKD | 3.77% |
| 2019 Q2 | -3.69 Million HKD | 0.0% |
| 2019 Q4 | -12.63 Million HKD | 0.0% |
| 2018 FY | -16.97 Million HKD | 1.42% |
| 2018 Q4 | -9.86 Million HKD | 0.0% |
| 2018 Q2 | -7.1 Million HKD | 0.0% |
| 2017 Q2 | -7.63 Million HKD | 0.0% |
| 2017 Q4 | -9.58 Million HKD | 0.0% |
| 2017 FY | -17.21 Million HKD | -14.72% |
| 2016 Q4 | -11.5 Million HKD | 0.0% |
| 2016 FY | -15 Million HKD | -3188.07% |
| 2016 Q2 | -3.5 Million HKD | 0.0% |
| 2015 Q1 | -7.14 Million HKD | 0.0% |
| 2015 Q4 | -2.43 Million HKD | 0.0% |
| 2015 Q2 | 2.91 Million HKD | 140.81% |
| 2015 FY | 486 Thousand HKD | 101.01% |
| 2014 Q2 | -6.48 Million HKD | -125.79% |
| 2014 Q1 | -2.87 Million HKD | 0.0% |
| 2014 Q3 | -7.14 Million HKD | -10.13% |
| 2014 Q4 | -7.14 Million HKD | 0.0% |
| 2014 FY | -48.2 Million HKD | -227.57% |
| 2013 FY | 37.78 Million HKD | 215.64% |
| 2013 Q4 | -2.87 Million HKD | 0.0% |
| 2013 Q3 | -2.87 Million HKD | -169.22% |
| 2013 Q2 | 4.15 Million HKD | 65.46% |
| 2013 Q1 | 2.5 Million HKD | 44.6% |
| 2012 Q2 | 2.11 Million HKD | 0.0% |
| 2012 Q1 | 2.11 Million HKD | 0.0% |
| 2012 Q4 | 1.73 Million HKD | -30.84% |
| 2012 FY | 11.97 Million HKD | 41.2% |
| 2012 Q3 | 2.5 Million HKD | 18.35% |
| 2011 FY | 8.47 Million HKD | 66.16% |
| 2011 Q1 | 2.34 Million HKD | 0.0% |
| 2011 Q2 | 2.34 Million HKD | 0.0% |
| 2011 Q3 | 2.11 Million HKD | -9.65% |
| 2011 Q4 | 2.11 Million HKD | 0.0% |
| 2010 FY | 5.1 Million HKD | -60.1% |
| 2010 Q1 | 4.57 Million HKD | 0.0% |
| 2010 Q4 | 2.34 Million HKD | 0.0% |
| 2010 Q3 | 2.34 Million HKD | -48.7% |
| 2010 Q2 | 4.57 Million HKD | 0.0% |
| 2009 Q3 | 4.57 Million HKD | 69.74% |
| 2009 Q4 | 4.57 Million HKD | 0.0% |
| 2009 FY | 12.78 Million HKD | 60.03% |
| 2009 Q1 | 2.69 Million HKD | 0.0% |
| 2009 Q2 | 2.69 Million HKD | 0.0% |
| 2008 FY | 7.99 Million HKD | 212.51% |
| 2008 Q1 | 639.25 Thousand HKD | 0.0% |
| 2008 Q4 | 2.69 Million HKD | 0.0% |
| 2008 Q2 | 639.25 Thousand HKD | 0.0% |
| 2008 Q3 | 2.69 Million HKD | 321.55% |
| 2007 Q1 | -253.25 Thousand HKD | 0.0% |
| 2007 FY | 2.55 Million HKD | -73.08% |
| 2007 Q4 | 639.25 Thousand HKD | 0.0% |
| 2007 Q3 | 639.25 Thousand HKD | 352.42% |
| 2007 Q2 | -253.25 Thousand HKD | 0.0% |
| 2006 Q4 | -253.25 Thousand HKD | 0.0% |
| 2006 FY | 9.5 Million HKD | 24.92% |
| 2006 Q2 | 738.75 Thousand HKD | 0.0% |
| 2006 Q3 | -253.25 Thousand HKD | -134.28% |
| 2006 Q1 | 738.75 Thousand HKD | 0.0% |
| 2005 Q1 | -21.7 Million HKD | 0.0% |
| 2005 Q2 | -21.7 Million HKD | 0.0% |
| 2005 FY | 7.6 Million HKD | 108.88% |
| 2005 Q3 | 738.75 Thousand HKD | 103.4% |
| 2005 Q4 | 738.75 Thousand HKD | 0.0% |
| 2004 Q4 | -21.7 Million HKD | 0.0% |
| 2004 Q1 | -14.1 Million HKD | 0.0% |
| 2004 Q2 | -14.1 Million HKD | 0.0% |
| 2004 Q3 | -21.7 Million HKD | -53.9% |
| 2004 FY | -85.63 Million HKD | -169.85% |
| 2003 Q1 | 9.01 Million HKD | 0.0% |
| 2003 FY | -31.73 Million HKD | -155.33% |
| 2003 Q4 | -14.1 Million HKD | 0.0% |
| 2003 Q3 | -14.1 Million HKD | -256.46% |
| 2003 Q2 | 9.01 Million HKD | 0.0% |
| 2002 FY | 57.35 Million HKD | 11.17% |
| 2002 Q4 | 9.01 Million HKD | 0.0% |
| 2002 Q3 | 9.01 Million HKD | -21.61% |
| 2002 Q2 | 11.49 Million HKD | 0.0% |
| 2002 Q1 | 11.49 Million HKD | 0.0% |
| 2001 FY | 51.59 Million HKD | 89.62% |
| 2001 Q4 | 11.49 Million HKD | 0.0% |
| 2001 Q3 | 11.49 Million HKD | 94.7% |
| 2001 Q2 | 5.9 Million HKD | 0.0% |
| 2001 Q1 | 5.9 Million HKD | 0.0% |
| 2000 Q4 | 5.9 Million HKD | 0.0% |
| 2000 Q3 | 5.9 Million HKD | 69.05% |
| 2000 Q2 | 3.49 Million HKD | 0.0% |
| 2000 Q1 | 3.49 Million HKD | 0.0% |
| 2000 FY | 27.2 Million HKD | 53.66% |
| 1999 Q3 | 3.49 Million HKD | 0.0% |
| 1999 Q4 | 3.49 Million HKD | 0.0% |
| 1999 FY | 17.7 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 105.707% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 100.306% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 119.966% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 84.359% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 122.646% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 102.63% |
| Tongfang Kontafarma Holdings Limited | - HKD | Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 87.642% |
| SSY Group Limited | 1.63 Billion HKD | 100.498% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 104.685% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 102.45% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.067% |